Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual ...

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it overcame side effects that had confounded its forerunner, the schizophrenia ...

(RTTNews) - PureTech Health PLC (PRTC) Friday said KarXT, invented by the company, received approval from U.S. Food and Drug Administration for the treatment of schizophrenia in adults. This ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...

The US Food and Drug Administration (FDA) is poised to regulate a "potential first-in-class antipsychotic", known as KarXT, said Medscape. About one in 300 people worldwide are affected by ...

Zai Lab (NASDAQ:ZLAB) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The FDA approved KarXT for schizophrenia in September. The drug will ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China to treat schizophrenia. The registrational bridging trial, which ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT ...

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT or xanomeline and trospium chloride, in China.